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hyperbilirubinemiaAbstract Purpose: To evaluate the difference in cerebral blood flow velocity
(CBFV) in neonates with and without hyperbilirubinemia.
Methods: CBFV of 70 healthy late-preterm and term newborns with unconjugated
hyperbilirubinemia (UCH) reaching the threshold of phototherapy requirement was
compared with 70 gestational- and postnatal age-matched controls without
hyperbilirubinemia. Resistance index (RI), pulsatility index (PI), peak systolic veloc-
ity (PSV) and vascular diameter were measured in internal carotid, vertebral and
middle cerebral arteries by transcranial color Doppler ultrasound at the beginning
of phototherapy, after 48–72 h of starting phototherapy and at 5–7 days after its
stoppage. In controls CBFV was assessed once at inclusion.
Results: Both the groups were comparable. An increase in CBFV (decreased RI and
PI, increased PSV and vasodilation) was observed in the UCH group. A further increase
in CBFV was noticed after 48 h of phototherapy. After 5–7 days of stoppage of pho-
totherapy, though there was a significant reduction in CBFV in mild-to-moderate UCH
(serum bilirubin 625 mg/dL), in severe UCH (serum bilirubin >25 mg/dL), CBFV
remained increased. Four neonates developed features of acute bilirubin encepha-
lopathy and had significantly higher CBFV compared to those with normal outcome.
Conclusions: An increase in CBFV was observed in neonates with UCH compared to
those without hyperbilirubinemia.
ª 2013 Ministry of Health, Saudi Arabia. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/1. Introduction
Unconjugated hyperbilirubinemia (UCH) remains
one of the most common clinical phenomena in
98 S. Basu et al.newborns. Approximately 60% of term and 80% of
preterm neonates develop UCH in the first week
of life [1]. There has been conflicting evidence
regarding the proportionate association of peak to-
tal serum bilirubin (TSB) with the future neurode-
velopmental delay [2,3]. The exact level of
bilirubin, likely to cause bilirubin-induced neuro-
logical dysfunction (BIND) in any individual baby,
is difficult to predict, and there is tremendous var-
iation in susceptibility toward bilirubin encepha-
lopathy among newborns for a variety of
unexplained reasons.
Bilirubin is a known biological antioxidant
which helps the newborn babies to cope with
the oxidative stress associated with birth [4].
The same bilirubin molecule mediates oxidative
stress and cerebral damage at higher serum con-
centrations [5]. In recent years, a resurgence of
BIND has been noted because of early postnatal
discharge and relaxation of attitudes toward
neonatal jaundice [6]. The various factors found
to be responsible for bilirubin-mediated neuro-
toxicity include the release of pro-inflammatory
cytokines from astrocytes and microglia [7,8],
disruption of glutathione redox status [9], in-
creased expression of neuronal nitric oxide syn-
thase (nNOS) and production of nitric oxide
(NO), cyclic guanosine 3 0,5 0-monophosphate
(cGMP) and reactive oxygen species (ROS)
[10,11]. Since all of these factors have the po-
tential to alter cerebral blood flow (CBF), it
was hypothesized that there may be some dif-
ference in cerebral blood flow velocity (CBFV)
in otherwise healthy neonates with hyperbilirubi-
nemia compared with those without any
icterus.
Unfortunately, there is no easily available, bed-
side tool which can depict cerebral dysfunction in
neonatal UCH. Magnetic resonance imaging (MRI)
of the brain may be an option to pick up neurolog-
ical abnormality early, but it is expensive and not
easily available in all centers of a developing coun-
try. To date, several studies have documented in-
creased CBFV after phototherapy [12–14], but it
is not clear whether there is any alteration of CBFV
in healthy neonates with UCH compared with those
without it. Hammerman et al. have even docu-
mented that different phototherapy delivery
modalities can have differential effects on CBFV
in term neonates. In their study, peak systolic CBFV
increased during treatment in infants treated un-
der overhead phototherapy but not in those trea-
ted in fluorescent BiliBed phototherapy units [15].
In the present study, CBFV in neonates with non-
hemolytic UCH before and after phototherapy wascompared with that of healthy neonates without
any jaundice.
2. Methods
2.1. Study population
This prospective observational study was con-
ducted over a period of 18 months in a tertiary care
reference teaching hospital after receiving ap-
proval from the Institutes Ethics Committee. The
study group comprised of consecutively admitted
healthy late preterm (35–36 weeks) and term
(37–41 weeks) newborns with non-hemolytic UCH
reaching the threshold of phototherapy require-
ment as per the guidelines of the American Acad-
emy of Pediatrics nomogram [16]. UCH was
defined as direct reacting fraction of bilirubin less
than 20% of TSB. Both inborn and home-delivered
neonates were included, provided they did not re-
ceive phototherapy or any other intervention for
UCH before being referred to this hospital. Conven-
tional phototherapy units (PT 2105, lamp series
2100, Zeal Medical, India) were used, positioned
18–20 cm above the infant, delivering a spectral
irradiance (measured by radiometer at the level
of the infant) of 10–12 lW per square centimeter
per nanometer in the 430–490 nm band. Photo-
therapy was stopped as per the same guidelines.
Neonates with perinatal asphyxia, systemic disor-
ders, sepsis, shock, hypoalbuminemia (serum albu-
min <3.0 g/dL), intracranial pathology or
malformation and other congenital anomalies were
excluded. Healthy gestational age and postnatal
age matched neonates without clinical hyperbiliru-
binemia served as controls. A written informed
consent in the local language was taken from all
parents at inclusion.
Any demographic details and antenatal investi-
gations that were done, including fetal Doppler
velocimetry, were recorded. Total, direct and indi-
rect serum bilirubin, blood group of the mother and
baby, hemoglobin, complete blood count, periphe-
ral blood smear examination, reticulocyte count,
Coombs test, free T4 and TSH and G6PD assay were
done in all cases before inclusion into the study.
TSB was repeated 6–12 hourly once phototherapy
was started. Other investigations were done as
and when necessary. In the UCH group, CBFV was
assessed thrice in each neonate, at inclusion be-
fore starting phototherapy, after 48–72 h of photo-
therapy and again at 5–7 days after stoppage of
phototherapy. Neonates who required photother-
apy for less than 48 h were also excluded. In con-
trols, CBFV was assessed once at inclusion. During
Cerebral blood flow velocity and neonatal hyperbilirubinemia 99hospital stay, neonates with UCH were closely ob-
served for the development of acute bilirubin
encephalopathy (ABE) and any other complication
until discharge. ABE was defined as the develop-
ment of abnormal muscle tone, mental status and
cry pattern (BIND score >3) [17]. Progress during
the hospital stay and outcome was noted.
2.2. Assessment of cerebral blood flow
velocity (CBFV)
All the Doppler examinations were conducted by a
single observer to avoid any inter-observer varia-
tion. The radiologist was blinded for the clinical
details, UCH subgroups and bilirubin values. Resis-
tance index (RI), pulsatility index (PI), peak systolic
velocity (PSV) and vascular diameter were mea-
sured in internal carotid arteries (ICA), vertebral
arteries (VA) and middle cerebral arteries (MCA)
of both sides by using TOSHIBA NEMIO-30 Ultra-
sound and Color Doppler machine with high fre-
quency linear array (8 MHz for ICA and VA) and
curvilinear array (3.75 MHz for MCA) transducer.
All measurements were done in thermo-neutral
environment in calm and quiet infants. The infants
were swaddled and oral dextrose was used as a
pacifier to make the infants quiet. RI and PI were
calculated as per the pre-defined formulae [18].
The value of each CBFV parameter was assessed
thrice before the mean value was entered in the
data sheet. In the absence of any statistically sig-
nificant variation between the CBFV of both sides
of the same artery, a mean value was calculated
for each parameter.
2.3. Sample size calculation
With an alpha of 0.05 and a beta of 0.80, a
minimum sample size of 44 newborns per group
was calculated to detect a difference of at least
3 cm/s in the mean PSV values between the groups
(two-tailed test).
2.4. Statistical analysis
The statistical program SPSS version 16.0 (SPSS
Inc., Chicago, IL) was used for data entry and anal-
ysis. Independent samples T test, Mann–Whitney
test and Chi Square test were used to compare con-
tinuous and categorical variables between groups.
ANOVA and post hoc Bonferroni Test were used to
make a comparison among multiple groups. Sensi-
tivity, specificity, positive and negative predictive
values (PPR and NPR) and positive and negative
likelihood ratios (PLR and NLR) of different CBFVparameters were calculated at selected cut-off
values. A p-value of <0.05 was considered statisti-
cally significant.
3. Results
The final study group comprised of 70 neonates
with UCH and 70 controls. Both groups were com-
parable with respect to their birth weight, gesta-
tional age, gender, postnatal age of inclusion and
other perinatal variables (Table 1). The majority
of the infants was exclusively breastfed in both
groups; none of the babies had a weight loss >10%
of the birth weight at the time of inclusion. Mean
arterial blood pressure (MAP) was maintained
above 50 mm of Hg throughout the study. None of
the study infants developed an opening of the duc-
tus arteriosus or intracranial hemorrhage during
the study period.
Table 2 summarizes the mean CBFV at inclusion
before starting phototherapy, 48 h after initiation
of phototherapy, and 5–7 days after stoppage of
phototherapy. It was found that RI and PI of all
cerebral arteries were significantly lower, and
PSV and vascular diameters were significantly
higher in the UCH group compared with controls
even before initiation of phototherapy. On overall
analysis of the UCH group, a significant increase
in the mean CBFV was observed after 48 h of photo-
therapy, compared with the pre-phototherapy lev-
els of the same group. However, CBFV decreased
significantly 5–7 days after the stoppage of
phototherapy.
For subgroup analysis, the neonates with UCH
were divided into four subgroups as per the TSB val-
ues at inclusion; subgroup 1 had TSB > 12–16 mg/dL
(n = 18), subgroup 2 had TSB > 16–20 mg/dL
(n = 23), subgroup 3 had TSB > 20–25 mg/dL
(n = 21) and subgroup 4 had TSB > 25 mg/dL (n = 8).
Figs. 1A–D showed the subgroup analysis of CBFV
changes over time. When compared with the initial
values, a significant increase in CBFV after 48–72 h
of phototherapy was observed in subgroups 1–3,
but a significant reduction was noted 5–7 days after
its stoppage. On the contrary, though a similar re-
sponse was observed in CBFV of subgroup 4 after
48–72 h of starting phototherapy, no reduction in
CBFV was noted 5–7 days after its stoppage.
Four neonates (6.7%) in the UCH group
developed features of ABE during their hospital
stay. Their CBFV was significantly higher at inclu-
sion before starting phototherapy compared with
neonates with a normal outcome (Table 3). There
was no difference in the mean gestational age,
birth weight and serum albumin in neonates with
Table 1 Comparison of neonatal and maternal demographic parameters between unconjugated hyperbilirubinemia (UCH)
and control groups.
Parameter UCH group (n = 70) Control group (n = 70) p Value
Birth weight (g) (mean ± SD) 2344 ± 526 2483 ± 609 0.150a
Gestational age (weeks) (mean ± SD) 36.3 ± 2.2 36.6 ± 2.8 0.426a
Male: Female 37: 33 41: 29 0.609b
Maternal age (years) (mean ± SD) 26.4 ± 3 26.5 ± 3.5 0.877a
Antenatal care taken, n (%) 42 (60) 45 (64.3) 0.727b
Gravida, Median 2 2 0.784a
(IQR) (1–3) (1–3)
Parity, Median 1 1 0.565a
(IQR) (0–2) (0–2)
Mode of delivery
SVD, n (%) 35 (50.0) 38 (54.3) 0.735b
Cesarean section, n (%) 35 (50.0) 32 (45.7)
Presentation
Vertex 67 (95.7) 68 (97.1) 1.000b
Breech 3 (4.3) 2 (2.9)
Apgar score, Median
(Range)
8
(7–9)
9
(7–10)
1.000b
Postnatal age at inclusion (days)
Median 3.8 3.5
IQR (2–5) (2–5) 0.842a
Feeding
Exclusive breastfeeding, n (%) 41 (58.6) 36(51.4) 0.753b
Topfeeding, n (%) 3 (4.3) 4 (5.7)
Mixed feeding, n (%) 26 (37.1) 30 (42.9)
SD, standard deviation; IQR, inter quartile range; SVD, spontaneous vaginal delivery.
a Independent samples T test.
b Chi square test; NS, not significant.
Table 2 Comparison of total serum bilirubin and blood flow velocity of different cerebral arteries between unconjugated
hyperbilirubinemia and control groups (mean ± SD).
Parameter Unconjugated hyperbilirubinemia group (n = 70) Control group
(n = 70)
ANOVA
(p value)Before PHT
(group A)
48 ± h After
beginning of
PHT (group B)
5–7 ± days after
stoppage of
PHT (group C)
Total serum bilirubin (mg/dL) 18.42 ± 3.82 13.54 ± 3.24 6.72 ± 2.64 - <0.001
Hemoglobin (g/dL) 16.9 ± 1.2 16.6 ± 2.0 16.6 ± 1.4 16.8 ± 2.3 <0.001
ICA RI 0.47 ± 0.07 0.39 ± 0.07 0.63 ± 0.14 0.65 ± 0.08 <0.001
VA RI 0.57 ± 0.09 0.48 ± 0.08 0.71 ± 0.15 0.74 ± 0.08 <0.001
MCA RI 0.66 ± 0.10 0.57 ± 0.09 0.81 ± 0.16 0.85 ± 0.08 <0.001
ICA PI 0.82 ± 0.07 0.72 ± 0.08 1.01 ± 0.23 1.04 ± 0.11 <0.001
VA PI 0.90 ± 0.10 0.80 ± 0.08 1.12 ± 0.22 1.17 ± 0.12 <0.001
MCA PI 1.03 ± 0.11 0.91 ± 0.10 1.22 ± 0.23 1.28 ± 0.13 <0.001
ICA PSV (cm/s) 91.33 ± 15.25 104.74 ± 15.76 57.72 ± 28.36 47.25 ± 7.58 <0.001
VA PSV (cm/s) 87.48 ± 12.32 101.71 ± 14.96 55.50 ± 28.89 45.18 ± 7.59 <0.001
MCA PSV (cm/s) 85.12 ± 11.82 98.58 ± 13.48 52.86 ± 26.85 42.88 ± 7.85 <0.001
ICA D (mm) 3.0 ± 0.28 3.19 ± 0.28 2.85 ± 0.36 2.77 ± 0.25 <0.001
VA D (mm) 2.91 ± 0.28 3.02 ± 0.29 2.68 ± 0.35 2.60 ± 0.24 <0.001
MCA D (mm) 2.77 ± 0.28 2.91 ± 0.31 2.54 ± 0.40 2.42 ± 0.25 <0.001
SD, standard deviation; PHT, phototherapy; TSB, total serum bilirubin; ICA, internal carotid artery; VA, vertebral artery; MCA,
middle cerebral artery; RI, resistance index; PI, pulsatility index; PSV, peak systolic velocity; D, diameter.
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Fig. 1A Comparison of resistance indices (RI) between subgroups of unconjugated hyperbilirubinemia. ICA, internal
carotid artery; VA, vertebral artery; MCA, middle cerebral artery; TSB, total serum bilirubin (mg/dL). *p < 0.05.
Fig. 1B Comparisons of pulsatility indices (PI) between subgroups of unconjugated hyperbilirubinemia. ICA, internal
carotid artery; VA, vertebral artery; MCA, middle cerebral artery; TSB, total serum bilirubin (mg/dL). *p < 0.05.
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Fig. 1C Comparisons of peak systolic velocities (PSV) between subgroups of unconjugated hyperbilirubinemia. ICA,
internal carotid artery; VA, vertebral artery; MCA, middle cerebral artery; TSB, total serum bilirubin (mg/dL).
*p < 0.05.
Fig. 1D Comparisons of vascular diameters (D) between subgroups of unconjugated hyperbilirubinemia. ICA, internal
carotid artery; VA, vertebral artery; MCA, middle cerebral artery; TSB, total serum bilirubin (mg/dL). *p < 0.05.
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Table 4 Predictive value of cerebral blood flow velocity parameters in unconjugated hyperbilirubinemia with acute
bilirubin encephalopathy.
Parameters Cut-off Sensitivity
(%)
Specificity
(%)
PPV (%)
(95% CI)
NPV (%)
(95% CI)
PLR
(95% CI)
NLR
(95% CI)
ICA RI 0.35 100 97.06 66.67
(22.68–94.67)
100.00
(94.51–100.00)
34
(8.68–133.19)
0.00
VA RI 0.40 100 98.53 80.00
(28.81–96.70)
100.00
(94.59–100.00)
68.00
(9.72–475.82)
0.00
MCA RI 0.50 100 95.59 57.14
(18.75–89.58)
100.00
(94.43–100.00)
22.67
(7.50–68.53)
0.00
ICA PI 0.70 100 97.06 66.67
(22.68–94.67)
100.00
(94.51–100.00)
34
(8.68–133.19)
0.00
VA PI 0.72 100 98.53 80.00
(28.81–96.70)
100.00
(94.59–100.00)
68.00
(9.72–475.82)
0.00
MCA PI 0.82 100 95.59 57.14
(18.75–89.58)
100.00
(94.43–100.00)
22.67
(7.50–68.53)
0.00
ICA PSV (cm/s) 127 100 98.53 80.00
(28.81–96.70)
100.00
(94.59–100.00)
68.00
(9.72–475.82)
0.00
VA PSV (cm/s) 110 100 98.53 80.00
(28.81–96.70)
100.00
(94.59–100.00)
68.00
(9.72–475.82)
0.00
MCA PSV (cm/s) 107 100 98.53 80.00
(28.81–96.70)
100.00
(94.59–100.00)
68.00
(9.72–475.82)
0.00
ICA D (mm) 3.45 100 98.53 80.00
(28.81–96.70)
100.00
(94.59–100.00)
68.00
(9.72–475.82)
0.00
VA D (mm) 3.35 100 97.06 66.67
(22.68–94.67)
100.00
(94.51–100.00)
34
(8.68–133.19)
0.00
MCA D (mm) 3.24 100 95.59 57.14
(18.75–89.58)
100.00
(94.43–100.00)
22.67
(7.50–68.53)
0.00
ICA, internal carotid artery; VA, vertebral artery; MCA, middle cerebral artery; RI, resistance index; PI, pulsatility index; PSV, peak
systolic velocity; D, diameter; NS, not significant; PPV, positive predictive value; NPV, negative predictive value; PLR, positive
likelihood ratio; NLR, negative likelihood ratio; CI, confidence interval.
Table 3 Comparison of blood flow velocity of different cerebral arteries at inclusion before starting phototherapy
between unconjugated hyperbilirubinemia with normal outcome and acute bilirubin encephalopathy (mean ± SD).
Parameter Unconjugated
hyperbilirubinemia with
normal outcome (n = 66)
Acute bilirubin
encephalopathy (n = 4)
Mann–Whitney U
Test (p value)
ICA RI 0.48 ± 0.07 0.32 ± 0.02 <0.001
VA RI 0.59 ± 0.08 0.35 ± 0.04 <0.001
MCA RI 0.68 ± 0.08 0.40 ± 0.03 <0.001
ICA PI 0.83 ± 0.07 0.67 ± 0.03 <0.001
VA PI 0.92 ± 0.10 0.6 ± 0.02 <0.001
MCA PI 1.04 ± 0.11 0.79 ± 0.03 <0.001
ICA PSV (cm/s) 89.04 ± 12.40 129.20 ± 5.37 <0.001
VA PSV (cm/s) 85.77± 10.40 115.90 ± 3.39 <0.001
MCA PSV (cm/s) 83.54 ± 10.16 111.35 ± 2.45 <0.001
ICA D (mm) 2.98 ± 0.26 3.52 ± 0.07 <0.001
VA D (mm) 2.89 ± 0.27 3.38 ± 0.02 <0.001
MCA D (mm) 2.74 ± 0.26 3.29 ± 0.04 <0.001
SD, standard deviation; ICA, internal carotid artery; VA, vertebral artery; MCA, middle cerebral artery; RI, resistance index; PI,
pulsatility index; PSV, peak systolic velocity; D, diameter.
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104 S. Basu et al.and without ABE. None of them had any associated
morbidity and sepsis. Table 4 showed high sensitiv-
ity, specificity, NPR and NLR of CBFV parameters in
predicting immediate poor outcome. However, PPV
and PLR were poor. There was no difference in
CBFV between boys and girls in any group (data
not shown).
4. Discussion
In the present study, an increase in CBFV in the
form of decreased resistance, increased blood flow
and vasodilation in neonates with significant non-
hemolytic UCH was observed compared with those
without icterus. An increase in CBFV was observed
after 48 h of phototherapy in the UCH group com-
pared with their own pre-phototherapy levels.
After 5–7 days of stoppage of phototherapy,
though there was a significant reduction in CBFV
in mild-to-moderate UCH (TSB 625 mg/dL), in se-
vere UCH (TSB >25 mg/dL), CBFV remained in-
creased. CBFV was significantly higher in neonates
who developed ABE (n = 4) compared with those
who had a normal outcome (n = 66). Though the
number of events was less, CBFV parameters dem-
onstrated high sensitivity, specificity, NPR and NLR
for predicting immediate poor outcome.
There is a paucity of literature regarding the
alteration of CBFV in UCH, though several authors
demonstrated an increase in CBFV after photother-
apy which came back to baseline after its discon-
tinuation [12–14]. Possible explanations have
been speculated to be the photo-relaxant effect
of phototherapy on blood vessels mediated by the
local production of NO with an increase in cGMP
[19], redistribution of blood flow causing a reduc-
tion of left ventricular output and increased CBF
[12], and increased heme oxygenase enzyme
expression by phototherapy light leading to an in-
creased production of carbon monoxide, which is
a potent dilator of neonatal cerebral microcircula-
tion [20,21]. Various theories of unconjugated bili-
rubin (UCB)-mediated neurotoxicity have been
speculated. Cytotoxic effects of UCB in selected
brain regions can be attributed to differences in
permeability of the blood–brain barrier (BBB) and
the blood–cerebrospinal fluid (CSF) barrier, regio-
nal blood flow, and rates of bilirubin oxidation
[22,23]. Recent evidences suggest that tight junc-
tions and transport mechanisms are already pres-
ent in the cellular interfaces between the blood,
brain, and CSF very early in the development. Dis-
ruption of these barrier mechanisms by UCB may
lead to brain damage and later neurological disor-
ders [24]. When the BBB is intact, the rate of bili-rubin uptake by the brain is determined by the
free bilirubin (Bf), the permeability and surface
area of the capillary endothelium, the transit time
through the capillary bed, the dissociation rate of
bilirubin–albumin, and the number of capillaries
recruited in a given region [22]. The BBB is quite
permeable to Bf, with single-pass uptakes esti-
mated as high as 28% in rats [25].
Persistently increased CBFV in this study was
probably indicative of neurotoxicity. Though the
exact reason of this increased CBFV is not known,
one likely mechanism could be bilirubin-mediated
oxidative stress. At higher levels, UCB is known to
induce protein oxidation and lipid peroxidation,
while it diminishes the thiol antioxidant defenses,
leading to cell death [26]. In vitro exposure of
astrocytes and neurons to free bilirubin modestly
above its aqueous saturation has been found to im-
pair a variety of cellular functions [27]. Inflamma-
tory pathways may also play a role in increasing
CBFV. When activated by UCB, astrocytes produce
inflammatory mediators such as TNF-a, IL-1b and
IL-6 [28], which may contribute to neurotoxicity
and cerebral vasodilation. UCB also activates dif-
ferent kinases and nuclear factor kappa-B cascade
which take part in the signaling events involved in
cytokine release [10,28]. Moreover, exposure to
UCB causes increased expression of neuronal NO
synthase and production of both NO and cGMP,
along with protein oxidation, caspase activation
and depletion of glutathione [7,28]. All these
events may lead to local vasodilation before cell
dysfunction and death.
In the present study, TCD ultrasound was used;
it is an inexpensive, non-invasive, bedside tool
which can be used easily. The changes of CBFV
were followed in the same cohort of neonates over
a period of time. All possible variables were ex-
cluded like perinatal asphyxia, shock, sepsis, ane-
mia, systemic and metabolic disorders, hypo/
hyperthermia and inter-observer variation which
could have influenced the results. Neonates
<35 weeks were also excluded as prematurity itself
can alter CBFV. The neonates with phototherapy
duration of less than 48 h were excluded as it was
presumed that the effect of phototherapy might
not be consistent if it was of short duration. How-
ever, this presumption was purely arbitrary; there
was no documented basis for this. The major limi-
tations of this study were that the long-term devel-
opmental outcome was not evaluated and no other
radiological investigations were performed, such as
an MRI. In addition, as CBFV is postnatal-age
dependent [29], the CBFV should have been evalu-
ated in controls at the same time as the UCH group
Cerebral blood flow velocity and neonatal hyperbilirubinemia 105for a more accurate interpretation of the results.
At the beginning, the postnatal age of estimation
of CBFV was similar in both the UCH group and
the controls, later on it was not possible to retain
healthy controls in the hospital only for research
purposes. There was actually no healthy age-
matched control population once phototherapy
was started. The alteration of CBFV in the UCH
group was compared with their own initial values.
Lastly, only four infants developed ABE. The inter-
pretation of the statistical validity tests against a
small number of events may not be accurate. No
adjustment was made for the duration of the pho-
totherapy or the exchange transfusion while mea-
suring the CBFV in neonates who developed ABE.
However, the increase in the CBFV was noted be-
fore these neonates developed features of ABE.
It is well known that the development of ABE is
determined by gestation, birth weight, associated
morbidity like sepsis and gastrointestinal obstruc-
tion, peak TSB, age at peak TSB, serum albumin,
and the presence of hemolysis [30,31]. Moreover,
it is the plasma non-protein-bound (unbound or
free) bilirubin concentration, rather than TSB,
which is more closely associated with central ner-
vous system bilirubin concentrations and therefore
ABE and its sequelae [32]. In the present study neo-
nates with and without ABE were similar with re-
spect to GA, BW and serum albumin. Neonates
with hemolytic anemias were excluded at the
beginning of the study and none of them had asso-
ciated sepsis. Free bilirubin was not assessed as
there was no facility to support such an
assessment.
To conclude, this study documents an increase
in CBFV in neonates with UCH compared with those
without it. An increase in CBFV was observed in the
UCH group after the institution of phototherapy
compared with their own pre-phototherapy levels.
Though CBFV parameters have shown major
changes in neonates with ABE, its predictive accu-
racy is questionable considering the small number
of events. A larger series may be considered to
study the statistical validity of CBFV as an early
predictor of impending neuronal damage in neona-
tal UCH.Conflict of interest
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